« Highlights of the 5-year results of ContinuationPV study presented at ASH20 showing long-term hematological and deep molecular responses with ropeginterferon including eradication of JAK mutation in selected patients »
Long term use of ropeginterferon alpha in Polycy... - MPN Voice
Long term use of ropeginterferon alpha in Polycythemia Vera
Written by
Manouche
To view profiles and participate in discussions please or .
1 Reply
•
Now if the FDA would just get on the ball, I could switch from Pegasys.
Not what you're looking for?
You may also like...
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
Discussion;
The results in our study demonstrate that the new dosing regimen of 250-350-500 µg of...
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
were the results?
Over a lifetime, the model showed that patients who received ropeginterferon...
Long-Term Use of Besremi in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
by selectively targeting the malignant clone. In the PROUD-PV/CONTINUATION-PV studies, long-term...
FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
company PharmaEssentia. Although their drug ropeginterferon alfa-2b is sold in the European Union...
FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera
a complete response letter regarding the biologics license application for ropeginterferon...
Related Posts
- Ropeginterferon Alfa-2b listed as Preferred Treatment in Polycythemia Vera
- ASH 2019 | Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results
- Interferon-Alpha Reduces Myelofibrosis Risk, Mortality Rate in Low- and High-Risk Polycythemia Vera
diagnosed with Polycythemia Vera 
Polycythemia Vera Leg Cramps
